A Pharmacokinetic Evaluation of Tenofovir/Emtricitabine as HIV Pre-Exposure Prophylaxis in Transgender Women
Status:
Completed
Trial end date:
2018-09-10
Target enrollment:
Participant gender:
Summary
Human immunodeficiency virus (HIV) persists worldwide as an immense health burden among
vulnerable populations. HIV pre-exposure prophylaxis (PrEP) has offered the promise of
limiting the global burden of HIV. The objective of this proposal is to conduct a
pharmacokinetic (PK) study in transgender women to describe the pharmacokinetics of tenofovir
disoproxil fumarate/emtricitabine (TDF/FTC) as PrEP within this population.